Deutsche Bank Starts Gen-Probe (GPRO) at Buy; Consummate Molecular Diagnostics 'Pro'

December 19, 2011 7:00 AM EST Send to a Friend
Get Alerts GPRO Hot Sheet
Price: $82.69 --0%

Rating Summary:
    4 Buy, 15 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 20 | New: 29
Trade GPRO Now!
Deutsche Bank initiates coverage on Gen-Probe (NASDAQ: GPRO) with a Buy. PT $70.50.

Deutsche analyst says, "GPRO is a leading player in the $4.5+ Bn MDx market, with a premier women's health and blood screening franchise. The company has a successful track record in launching automated testing instruments, having placed over 550 Tigris' in the five years post launch. FY12 is a significant transition year given the imminent launch of Panther (targeting mid vol labs), and a multitude of assays (HPV, Trich. and PCA3). Given our expectations for new product momentum to drive low double digit rev growth in the MT, we rate GPRO shares a Buy."

For an analyst ratings summary and ratings history on Gen-Probe click here. For more ratings news on Gen-Probe click here.

Shares of Gen-Probe closed at $56.50 yesterday, with a 52 week range of $53.92-$86.96.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Deutsche Bank

Add Your Comment